Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
Status:
Active, not recruiting
Trial end date:
2022-01-18
Target enrollment:
Participant gender:
Summary
The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease
(CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY
aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the
outcomes of people who tested positive for COVID-19 disease.